Automated data verification saves clinical teams a significant amount of cost, time, and effort.

Pleasanton, California, October 6th / PRNewswire / -- Veeva Systems (New York Stock Exchange ticker: VEEV) today announced that Veeva DQS ( Data Quality System, a data quality system) has aggregated and cleaned data for over 1 million participants across more than 1,000 studies, in order to accelerate the delivery of data and trial insights available for analysis. Veeva DQS has issued over 500,000 automated queries, saving research centers and sponsors thousands of hours of data verification work.

"For us, a key area is dealing with the increasingly large volume of data that arises as the number of clinical trials grows," said Vice President Ibrahim Kamstrup - Akkaoui, Novo. "Veeva DQS can help us manage, format, clean, and prepare this data more efficiently for submission."

Veeva DQS promotes the next generation of clinical data management by supporting the progress necessary for risk-based strategies recommended in regulatory guidelines, which includes ICH E6 ( R3 ). As Veeva DQS continues to introduce innovative features, clinical teams can:

• Faster access to high-quality data: Veeva DQS automated data workflows classify and visualize critical data, facilitate risk-based action orchestration within clinical ecosystems, and eliminate the need for manual data verification.
• Supports risk-based quality management ( RBQM ): Automated data exchange between Veeva DQS and Veeva CTMS enables immediate alerts to clinical operations teams to pay attention to key data changes, such as deviations from plans, and allows clinical data teams to calculate, track, and manage key risk indicators ( KRI ).
• Classify using the understanding of data and users' AI: Embed Veeva DQS within AI to accelerate the classification of research data and understand its purpose and significance. This enables the system to generate reports, lists, or test scripts, among other items, and to provide customized user experiences and workflows based on roles.

"As the number of data sources increases and the complexity of solutions rises, applicants and CRO are using Veeva DQS to automate data workflows on a large scale in various studies," said Pavel Burmenko, the strategic leader of Veeva DQS. " Veeva DQS is driving the next generation of data management, which represents a new level of clinical data innovation. It orchestrates risk-based reviews and elevates the role of data managers to that of strategic partners."

Veeva recently announced that Study Builder Agent can directly configure Veeva EDC and Veeva DQS according to the research plan, thereby completing the research setup more quickly and consistently. For more information about Study Builder Agent, Veeva DQS which has won SCDM Innovation Award, and how biopharmaceutical companies can drive clinical data innovation at the Veeva Research and Quality Summit, you can learn more on October 20th to 21st in Boston. This event is only open to professionals in the life sciences industry.

About Veeva Systems

Veeva provides industry cloud for the life sciences sector, covering applications, agency, data, and consulting services. Veeva is committed to innovation, product excellence, and customer success, serving over 1500 clients ranging from the world's largest pharmaceutical companies to emerging biotech firms. As a public interest company, Veeva strives to balance the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, please visit veeva.com.

Veeva Forward-looking Statement

This press release contains forward-looking statements regarding Veeva products and services, as well as the expected results or benefits from using such products and services. These statements are based on our current expectations. Actual results may differ significantly from those described in this press release, and we have no obligation to update these statements. There are numerous risks that may have a negative impact on our performance, including those disclosed in the 10-Q filing for the fiscal year ending July 31, 2026 (a summary of relevant risks can be found on pages 33 and 34), as well as in subsequent filings submitted to the U.S. Securities and Exchange Commission, which can be viewed at sec.gov.

Contact Information: